According to the research report, the USgeneric drug market size is expected to touch USD 721.54 Billion by 2032, from USD 435.54 Billion in 2022, growing with a significant CAGR of 721.54 % from 2022 to 2032.
The US generic drug market report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global US generic drug market in
conjunction with the geographical landscape of this vertical have also been
included in this report.
The report offers intricate dynamics about
different aspects of the global US generic drug market, which aids companies operating
in the market in making strategic development decisions. The study also
elaborates on significant changes that are highly anticipated to configure
growth of the global US generic drug market during the forecast period. It also
includes a key indicator assessment that highlights growth prospects of this
market and estimates statistics related to growth of the market in terms of
value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/2486
| Report Coverage | Details |
| Market Size in 2022 | USD 435.54 Billion |
| Market Size by 2032 | USD 721.54 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.18% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Type, By Route of Administration, By Therapeutic Application, By Distribution Channels |
This study covers a detailed segmentation
of the global US generic drug market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global US generic drug market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Pfizer Inc
- Teva Pharmaceuticals USA, Inc
- Aurobindo Pharma USA, Inc
- Sun pharma Inc
- Abbott Laboratories Inc
- Lupin Pharmaceuticals, Inc
- Mylan
- Dr. Reddy’s
- Novartis
- Eli Lilly company
Market Segmentation
- Pure Generic Drugs
- Branded Generic Drugs
By Route of Administration
- Oral
- Topical
- Parental
- others
By Therapeutic Application
- Cardiovascular
- Central nervous system (CNS)
- Dermatology
- Oncology
- Respiratory
- Others
By Distribution Channels
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Others
Research Methodology
The research methodology adopted by
analysts for compiling the global US generic drug market report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary
understanding of the global US generic drug market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US Generic Drug Market
5.1. COVID-19 Landscape: US Generic Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US Generic Drug Market, By Type
8.1. US Generic Drug Market, by Type, 2022-2032
8.1.1. Pure Generic Drugs
8.1.1.1. Market Revenue and Forecast (2022-2032)
8.1.2. Branded Generic Drugs
8.1.2.1. Market Revenue and Forecast (2022-2032)
Chapter 9. Global US Generic Drug Market, By Route of Administration
9.1. US Generic Drug Market, by Route of Administration, 2022-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2022-2032)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2022-2032)
9.1.3. Parental
9.1.3.1. Market Revenue and Forecast (2022-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2022-2032)
Chapter 10. Global US Generic Drug Market, By Therapeutic Application
10.1. US Generic Drug Market, by Therapeutic Application, 2022-2032
10.1.1. Cardiovascular
10.1.1.1. Market Revenue and Forecast (2022-2032)
10.1.2. Central nervous system (CNS)
10.1.2.1. Market Revenue and Forecast (2022-2032)
10.1.3. Dermatology
10.1.3.1. Market Revenue and Forecast (2022-2032)
10.1.4. Oncology
10.1.4.1. Market Revenue and Forecast (2022-2032)
10.1.5. Respiratory
10.1.5.1. Market Revenue and Forecast (2022-2032)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2022-2032)
Chapter 11. Global US Generic Drug Market, By Distribution Channels
11.1. US Generic Drug Market, by Distribution Channels, 2022-2032
11.1.1. Retail Pharmacies
11.1.1.1. Market Revenue and Forecast (2022-2032)
11.1.2. Online Pharmacies
11.1.2.1. Market Revenue and Forecast (2022-2032)
11.1.3. Hospital Pharmacies
11.1.3.1. Market Revenue and Forecast (2022-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2022-2032)
Chapter 12. Global US Generic Drug Market, Regional Estimates and Trend Forecast
12.1. U.S.
12.1.1. Market Revenue and Forecast, by Type (2022-2032)
12.1.2. Market Revenue and Forecast, by Route of Administration (2022-2032)
12.1.3. Market Revenue and Forecast, by Therapeutic Application (2022-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channels (2022-2032)
Chapter 13. Company Profiles
13.1. Pfizer Inc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceuticals USA, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Aurobindo Pharma USA, Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sun pharma Inc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbott Laboratories Inc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lupin Pharmaceuticals, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Mylan
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Dr. Reddy’s
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Eli Lilly company
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments